Lindhardt M, et al. - Whether the proteomic classifier based on 273 urinary peptides (CKD273) predicts albuminuria response to spironolactone treatment in patients with diabetes, was investigated herein. It was shown that individuals with type 2 diabetes who were more likely to exhibit an albuminuria-lowering response to spironolactone treatment could be identified using a urinary proteomics classifier. In addition, urinary proteomics may be a valuable tool to tailor therapy.